肺表面活性物质联合NCPAP治疗新生儿呼吸窘迫综合征  

Pulmonary Surfactant Combined with NCPAP for Neonatal Respiratory Distress Syndrome

作　　者：许志有 王耀霜 韩萍 符艺影 孔燕子 董战玲[2] 

机构地区：[1]海口市第三人民医院儿科,海口570102 [2]海南医学院生理教研室,海口571199

出　　处：《南昌大学学报（医学版）》2015年第6期55-57,共3页Journal of Nanchang University：Medical Sciences

基　　金：海南医学院培育基金(HY2010-005);海南省教育厅科研资助项目(Hj2007113);海南省重点科技项目(061011)

摘　　要：目的观察肺表面活性物质(pulmonary surfactant,PS)联合经鼻持续气道正压通气(nasal continuous positive airway pressure,NCPAP)治疗新生儿呼吸窘迫综合征(respiratory distress syndrome,RDS)的临床疗效。方法将52例RDS患儿按简单随机方法分成治疗组和对照组,每组26例。治疗组在常规治疗的基础上采用PS联合NCPAP治疗,对照组在常规治疗的基础上单独应用NCPAP治疗。结果 2组治疗后血气分析结果较治疗前均显著改善(均P<0.05),治疗组改善显著优于对照组(均P<0.05)。治疗组治愈率较对照组高,住院时间、病死率、机械通气应用率、肺部感染及气胸等并发症的发生率明显低于对照组(P<0.05或P<0.01)。结论采用PS联合NCPAP治疗RDS,能迅速有效地改善临床症状,缩短住院时间,降低病死率及并发症的发生,减少机械通气的应用。Objective To observe the clinical efficacy of pulmonary surfactant（PS）combined with nasal continuous positive airway pressure（NCPAP）in the treatment of neonatal respiratory distress syndrome（RDS）.Methods Fifty-two children with RDS were given conventional therapy.In addition,these children were treated with NCPAP alone（control group,n=26）or in combination with PS（treatment group,n=26）.Results The results of blood gas analysis were significantly improved after treatment in both groups（P〈0.05）.Compared with control group,blood gas analysis results were improved,cure rate was increased,hospital stay was shortened,and mortality rate,application rate of mechanical ventilation and incidence of pulmonary infection,pneumothorax and other complications were decreased in treatment group（P〈0.05 or P〈0.01）.Conclusion The combined treatment with PS and NCPAP for RDS can effectively improve the clinical symptoms,shorten the length of hospital stay,reduce the mortality and complications,and decrease the application of mechanical ventilation.

关 键 词：肺表面活性物质 呼吸窘迫综合征 新生儿 经鼻持续气道正压通气 

分 类 号：R722.12[医药卫生—儿科]